HER3 AS AN ADC TARGET: FROM OVERLOOKED RECEPTOR TO ONCOLOGY’S NEXT FRONTIER
In this week’s ADC Spotlight, Suhail Ahmed Kabeer Rasheed takes HER3 from “undruggable” to centre stage as one of oncology’s most compelling ADC targets. From EGFR‑mutant NSCLC to HR+/HER2– and triple‑negative breast cancer, HER3‑directed ADCs are showing that you don’t need kinase activity to create a therapeutic vulnerability, you need the right combination of epitope, […]
APTIMA HPV ASSAY
In this edition, Krishnangi explores the Aptima HPV Assay, an FDA PMA-approved molecular diagnostic assay designed for primary cervical cancer screening through detection of high-risk HPV E6/E7 messenger RNA. Through her coverage, Krishnangi highlights the assay’s transcription-mediated amplification workflow, its role in improving specificity for clinically significant HPV infections, and its broader potential to advance […]
Challenges and Opportunities in Neuroscience Clinical Trials
In recognition of International Clinical Trials Day, celebrated worldwide on May 20, this article explores the growing challenges and emerging opportunities shaping neuroscience clinical trials. From high cost and the complexity of translating animal-model success into human outcomes, the piece examines why CNS drug development remains one of the most demanding areas in clinical research. […]
2. Sample Preparation: (F) Prep Shapes the Panel
Sample preparation is never just a routine prelude to analysis—It is the exact stage where your panel’s biological truth succeeds or fails. In this article, Aditi Sharma created this master bubble map that connects the dots between all five chapters and has distilled every core takeaway into a single, high-level visual index for clarity and […]
Leaving the Tumor Behind: ADCs in Non-Oncology Indications
In this week’s ADC Spotlight, Suhail Ahmed Kabeer Rasheed takes the ADC platform somewhere it has rarely been pointed: outside the tumor. From rheumatoid arthritis and organ fibrosis to intracellular bacterial infections and neurodegeneration, ADCs are beginning to show that the three-part logic: antibody, linker, payload, is not inherently oncological. It is a precision delivery […]
2. Sample Preparation: (E) Handling Rare Cells
Handling rare populations is the pursuit of a “needle in a haystack,” requiring technical precision to transform scarce cellular events into statistically valid discovery. In this chapter, Aditi Sharma navigates the critical strategies needed to protect and amplify these precious targets. Disclaimer The editors take care to share authentic information. In case of any discrepancies […]
CLEVECORD- A New Benchmark in Stem Cell Therapy
In our latest FDA update, Shilpita Karmakar provides a concise overview of the clinical significance and broad applications of CLEVECORD in stem cell therapy. The report also outlines FDA-approved clinical trials and discusses potential adverse effects associated with its use. CLEVECORD has demonstrated utility in the management of hematological malignancies, immunological disorders, and gastrointestinal disorders. […]
2. Sample Preparation: (D) Staining
Staining is the technical bridge that transforms translucent cells into a measurable map of biological activity by labeling specific components with fluorophore-conjugated antibodies. In this article, Aditi Sharma navigates the decision tree of selecting staining methods. Disclaimer The editors take care to share authentic information. In case of any discrepancies please write to newsletter@medness.org. The […]
2: Sample Preparation(C) Single Cell Suspension
Flow cytometry is, by definition, the study of individual cells in a moving fluid stream. In this article, Aditi Sharma explores the critical prep steps that ensure your high-quality output is built on high-quality input. Disclaimer The editors take care to share authentic information. In case of any discrepancies please write to newsletter@medness.org. The sponsors […]
A shared Network Pattern in Major Depressive and Bipolar Depression Disorder
If two disorders have overlapping symptoms, does the brain see them differently?In this edition, Ritu Moni Borah covers this study from the Journal of Affective Disorders that put that question to the test. (Click anywhere on the image to expand) Disclaimer The editors take care to share authentic information. In case of any discrepancies please write to […]
Antibody-Oligonucleotide Conjugates: When the Payload is a Gene-Silencer
In this week’s ADC Spotlight, Suhail Ahmed Kabeer Rasheed asks what happens when you keep the antibody-drug conjugate chassis but swap the cytotoxin for a gene-silencer. Antibody–oligonucleotide conjugates (AOCs) use the same three-part logic—antibody, linker, payload—but instead of killing cells, they deliver siRNA, ASOs, or exon-skipping oligos to silence disease-driving genes in specific tissues. With del-desiran (AOC […]
Guardant360 CDx
Continuing her series on precision diagnostics shaping colorectal cancer care, Krishnangi turns her attention to the Guardant360 CDx, a next-generation sequencing based liquid biopsy companion diagnostic that enables detection of clinically actionable genomic alterations from circulating tumor DNA. Building on earlier discussions around tissue-based biomarker testing, this edition explores how blood-based genomic profiling is transforming […]
2. Sample Preparation: (B) Sample Storage
Sample storage is a critical step in flow cytometry workflows, because delays and improper handling can quickly alter cell viability, marker expression, and data quality. In this article, Aditi Sharma outlines practical storage strategies for short- and long-term preservation so you can match your sample handling to your experimental timeline. (Click anywhere on the image […]
Nav1.8 and Suzetrigine
The FDA approved Suzetrigine in January 2025, the first new class of non-opioid pain drug in 25 years. It works by blocking Nav1.8, a sodium channel found almost exclusively in peripheral pain-sensing nerves. This article by Vandana Mishra traces the full story: why Nav1.8 became a target, how suzetrigine was designed to block it with […]
Beyond Cytotoxins: Immunostimulatory and Non-Cytotoxic Payloads in ADC Design
ADCs are moving beyond “smart chemotherapy.” From STING and TLR agonists to targeted protein degraders and oligonucleotides, this MedNess ADC Spotlight article by Suhail Ahmed Kabeer Rasheed explores how non-cytotoxic payloads are redefining what precision oncology could look like: focused on immune activation and tumor reprogramming rather than direct cell kill. (Click anywhere on the […]
2. Sample Preparation: (A) Sample Collection
In this issue of Flow Focus, Aditi Sharma introduces the fundamentals of sample preparation for flow cytometry, emphasizing best practices for collecting and processing samples and highlighting key choices to generate viable, clean single‑cell suspensions. (Click anywhere on the image to expand) Disclaimer The editors take care to share authentic information. In case of any discrepancies please write […]
From Monotherapy to Backbone: How ADCs Are Anchoring First-Line Treatment
In this week’s ADC Spotlight, Suhail Ahmed Kabeer Rasheed argues that the real frontier in ADC development is no longer a better single agent, but a better-designed combination backbone. From urothelial carcinoma and DLBCL to HER2‑driven disease, ADCs have moved from late‑line rescue to anchoring first‑line regimens, yet not every pairing makes strategic sense. This […]
Defining Key Flow Cytometry Terms – Part 2
In this installment, Aditi Sharma breaks down the essential terminology that governs the internal mechanics of the flow cytometer. By anchoring your expertise in these core technical concepts, you can better navigate the transition from simple analysis to complex FACS sorting. (Click anywhere on the image to expand) Disclaimer The editors take care to share authentic […]
ALLOCORD LIFE SAVER
In our latest FDA feed, Shilpita Karmakar offers a concise overview of the clinical significance and wide application of ALLOCORD as regenerative medicine. This report also highlights an outline of FDA-approved clinical trials and potential adverse effects of ALLOCORD use. Beyond its role in hematological malignancies, ALLOCORD has also been established for the management of […]
1. Experimental Design: (G) Scaling Up
Scaling a flow cytometry project requires more than just increasing the number of samples; it demands a transition from simply handling a greater volume to building a reliable, quantitative measurement framework. In this article, Aditi Sharma outlines actionable, high-impact strategies for evolving projects from initial exploratory panels through successful validation studies and, ultimately, to use […]
Opening a New Era for Gynecologic Cancers: Elahere
In this edition of ADC Spotlight, Sneha explores Elahere, the first FDA approved FRα-directed ADC developed to address a significant unmet medical need in platinum-resistant ovarian cancer. By selectively targeting folate receptor-α, a marker highly expressed on tumor cells, Elahere brings meaningful therapeutic precision to a disease with few effective options. This snapshot captures its […]
Generalized Anxiety Disorder: Clinical Trials
From LSD-derivatives to triple-action pills, the GAD pipeline is undergoing a radical shift. This article explores how Phase III clinical trials are targeting the misfiring of the brain’s emotional and executive circuits to move beyond traditional treatments. (Click anywhere on the image to expand) Disclaimer The editors take care to share authentic information. In case […]
Can Digital Health Reduce Healthcare Inequality — or Widen It?
Digital health technologies such as telemedicine, AI diagnostics, wearable devices, and mobile health platforms are transforming healthcare delivery across the world. In this article, I explore an important issue often overlooked in the innovation conversation — healthcare inequality. The piece discusses:• How digital health can expand care access in rural and underserved communities• The growing […]
HIV Capsid and Lenacapavir: A breakthrough in HIV treatment
For decades, HIV drugs focused on viral enzymes. Lenacapavir changed that by targeting the virus’s structural core. This article traces how the HIV capsid, once thought to be a passive shell, emerged as a dynamic and essential driver of infection, and how structure-guided research turned it into a powerful drug target. From capsid architecture and […]
ANXIETY DISORDER: GENERALIZED ANXIETY DISORDER
Anxiety, characterized by prediction of a future threat, is a vital survival feature and emotional state. It is the brain’s way of keeping us alive. However, when we begin associating routine events with danger, this constant anticipation can backfire, resulting in profound mental distress and fatigue. This persistent worry is the hallmark of Generalized Anxiety Disorder […]
Fc-Glycan-Directed ADCs: The Platform Behind the Headlines
In this week’s ADC Spotlight, Suhail Ahmed Kabeer Rasheed unpacks Fc‑glycan–directed ADCs—the site‑specific, hydrophilic conjugation platforms quietly powering a growing class of antibody–drug conjugates. Using HMBD‑501’s first‑in‑human milestone as a timely hook, he explains how enzymatic glycan remodelling and metal‑free click chemistry turn the Fc sugar into a portfolio‑wide docking hub, and highlights clinical gsADCs […]
Charting New Territory with a Novel TF Target: Tivdak
In this edition of ADC Spotlight, Sneha explores Tivdak, the first ADC approved for cervical cancer and the first to target tissue factor (TF). By coupling targeted TF binding with the potent MMAE payload, Tivdak delivers cytotoxic precision while disrupting key tumor-promoting pathways. This snapshot captures its story from development to impact, highlighting how Tivdak […]
IDYLLA™ CDx MSI TEST
In this edition, Krishnangi examines the Idylla™ CDx MSI Test, a recently FDA PMA-approved companion diagnostic for microsatellite instability in colorectal cancer. Through her coverage, Krishnangi outlines the assay’s fully automated cartridge-based workflow, its role in guiding immunotherapy selection, and its broader potential to expand access to rapid, decentralized molecular testing across routine pathology and hospital laboratory settings. (Click […]
THE NEW HORIZON WITH STEM CELL
In our latest FDA feed, Shilpita Karmakar offers a comprehensive overview of the significance of stem cell therapy and their potential implications in regenerative medicine, along with an outline of FDA-approved regulatory guidelines. Currently, most of the FDA-approved stem cell therapies are based on hematopoietic progenitor cells, which are primarily used for bone marrow transplants […]
DISSOCIATIVE IDENTITY DISORDER
We experience ourselves as a single personality, and that is our reality, but is it true? This is a difficult concept to reconcile with Dissociative Identity Disorder (DID), formerly known as Multiple Personality Disorder. This article explores the nature of DID, including its symptoms, diagnosis, treatment, associated brain alterations, and unique challenges. (Click anywhere on […]